Related Experiment Video
Updated: Jun 14, 2025
Author Spotlight: Understanding the Propagation of Closed Circular Extrachromosomal rDNA Containing Element (CERE) in Naegleria gruberi
Published on: June 21, 2024
Approaches for Targeting Naegleria fowleri Using Nanoparticles and Artificial Peptides
Hayley Fong1, Zachary H Leid1, Anjan Debnath1
1Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA.
Abstract:
Naegleria fowleri is a free-living amoeba which causes primary amoebic meningoencephalitis (PAM). Although PAM is rare, the fatality rate is staggering at over 97%. So, the importance of finding an effective treatment and cure for PAM caused by N. fowleri is a crucial area of research. Existing research on developing novel therapeutic strategies to counter N. fowleri infection is limited. Since the blood-brain barrier (BBB) presents an obstacle to delivering drugs to the site of infection, it is important to employ strategies that can effectively direct the therapeutics to the brain. In this regard, our review focuses on understanding the physiology and mechanisms by which molecules pass through the BBB, the current treatment options available for PAM, and the recent research conducted in the decade of 2012 to 2022 on the use of nanomaterials to enhance drug delivery. In addition, we compile research findings from other central nervous system (CNS) diseases that use shuttle peptides which allow for transport of molecules through the BBB. The approach of utilizing BBB shuttles to administer drugs through the BBB may open up new areas of drug discovery research in the field of N. fowleri infection.
Insights
Primary amoebic meningoencephalitis (PAM) is a rare but deadly infection caused by Naegleria fowleri. This review explores using nanomaterials and shuttle peptides to overcome the blood-brain barrier for effective PAM treatment.
Area of Science:
- Neuroscience
- Infectious Diseases
- Nanotechnology
Background:
- Naegleria fowleri causes primary amoebic meningoencephalitis (PAM), a rare infection with a >97% fatality rate.
- Effective treatment development for PAM is crucial due to limited therapeutic options and high mortality.
- The blood-brain barrier (BBB) impedes drug delivery to the brain, complicating treatment for CNS infections like PAM.
Purpose of the Study:
- To review current treatments for PAM and explore novel therapeutic strategies.
- To understand mechanisms of BBB penetration for drug delivery.
- To assess the potential of nanomaterials and shuttle peptides for treating N. fowleri infections.
Main Methods:
- Literature review of research from 2012-2022 on nanomaterials for drug delivery.
- Analysis of studies on shuttle peptides for BBB transport in CNS diseases.
- Examination of N. fowleri physiology and PAM treatment options.
Main Results:
- Nanomaterials show promise for enhancing drug delivery across the BBB.
- Shuttle peptides offer a viable strategy for transporting therapeutics to the brain.
- Limited research exists on direct application of these methods to N. fowleri infections.
Conclusions:
- Overcoming the BBB is critical for effective PAM treatment.
- Nanomaterials and shuttle peptides represent promising avenues for novel drug delivery strategies.
- Further research is needed to develop targeted therapies for Naegleria fowleri infections using these advanced delivery systems.
More Related Videos
09:04Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
Published on: September 21, 2017
07:33Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
Published on: September 28, 2022